Fertility and Sterility
Volume 92, Issue 4 , Pages 1351-1354 , October 2009

Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age

Received 22 July 2008 ,Revised 30 July 2008 ,Accepted 7 August 2008.

References 

  1. Mohan S, Page LM, Higham JM. Diagnosis of abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol. 2007;21:891–903
  2. Bachmann G, Korner P. Bleeding patterns associated with oral contraceptive use: a review of the literature. Contraception. 2007;76:182–189
  3. Robins JC. Therapies for the treatment of abnormal uterine bleeding. Curr Womens Health Rep. 2001;1:196–201
  4. Koh SC, Singh K. The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia. J Thromb Haemost. 2007;5:133–138
  5. Beaumont H, Augood C, Duckitt K, Lethaby A. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev. 2007;3:CD001017
  6. Chimbira TH, Anderson AB, Naish C, Cope E, Turnbull AC. Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lack of effect of placebo. Br J Obstet Gynaecol. 1980;87:1152–1158
  7. Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. Br J Obstet Gynaecol. 1989;96:840–844
  8. Higham JM, Shaw RW. A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. Am J Obstet Gynecol. 1993;169:1134–1139
  9. Nafarelin European Endometriosis Trial Group (NEET). Nafarelin for endometriosis: A large scale, danazol-controlled trial of efficacy and safety, with 1-year follow up. Fertil Steril. 1992;57:514–522
  10. Mais V, Cossu E, Angioni S, Piras B, Floris L, Melis GB. Abnormal uterine bleeding: medical treatment with vaginal danazol and five-year follow-up. J Am Assoc Gynecol Laparosc. 2004;11:340–343
  11. Guerriero S, Paoletti AM, Ajossa S, et al. Influence of vaginal danazol on uterine and brain perfusion during hormonal replacement therapy. Menopause. 2001;8:424–428
  12. Razzi S, Luisi S, Calonaci F, Altomare A, Bocchi C, Petraglia F. Efficacy of vaginal danazol treatment in women with recurrent deeply infiltrating endometriosis. Fertil Steril. 2007;88:789–794
  13. Larroy C. Comparing visual analog and numeric scales for assessing menstrual pain. Behav Med. 2002;27:179–181
  14. Cobellis L, Razzi S, Fava A, Severi FM, Igarashi M, Petraglia F. A danazol-loaded intrauterine device decreases dysmenorrhea, pelvic pain, and dyspareunia associated with endometriosis. Fertil Steril. 2004;82:239–240
  15. Mizutani T, Nishiyama S, Amakawa I, Watanabe A, Nakamuro K, Terada N. Danazol concentrations in ovary, uterus, and serum and their effect on the hypothalamic-pituitary-ovarian axis during vaginal administration of a danazol suppository. Fertil Steril. 1995;63:1184–1189
  16. Telimaa S, Apter D, Reinila M, Ronnberg L, Kauppila A. Placebo-controlled comparison of hormonal and biochemical effects of danazol and high-dose medroxyprogesterone acetate. Eur J Obstet Gynaecol Reprod Biol. 1990;36:97–105
  17. Ledford MR, Horton A, Wang G, Brito M, Delgado L. Efficacy of danazol in a patient with congenital protein-S deficiency: paradoxical evidence for decreased platelet activation with increased thrombin generation. Thromb Res. 1997;87:473–482

 S.L. has nothing to disclose. S.R. has nothing to disclose. L.L. has nothing to disclose. C.B. has nothing to disclose. F.S. has nothing to disclose. F.P. has nothing to disclose.

PII: S0015-0282(08)03361-X

doi: 10.1016/j.fertnstert.2008.08.017

Fertility and Sterility
Volume 92, Issue 4 , Pages 1351-1354 , October 2009

Article Tools

* Image Usage & Resolution